| Document |
Document Title |
|
WO/2023/058737A1 |
The present invention addresses the issue of providing an enteritis-suppressing composition. The issue is solved by an enteritis-suppressing composition that contains at least one type selected from the group consisting of sesaminol and ...
|
|
WO/2023/058801A1 |
The present invention provides a composition which comprises at least one selected from a group consisting of a Lactobacillus acidophilus KBL402 strain with accession number KCTC 14640BP or a Lactobacillus acidophilus KBL409 strain with ...
|
|
WO/2023/058705A1 |
The present invention pertains to an anti-HLA-DQ2.5 antibody and a drug formulation containing the anti-HLA-DQ2.5 antibody. The present invention provides a modified anti-HLA-DQ2.5 antibody. The anti-HLA-DQ2.5 antibody according to the p...
|
|
WO/2023/056469A2 |
Provided are engineered lipase enzymes, methods of making such engineered lipases, dosage forms containing such engineered lipases and, methods of using such engineered lipases for treating diseases or disorders associated with reduced a...
|
|
WO/2023/053384A1 |
The inventors of the present invention have found that HMGB1-derived peptides can be used as a therapeutic drug and/or a prophylactic drug for fatty liver, nonalcoholic steatohepatitis, and various symptoms associated with fatty liver. O...
|
|
WO/2023/053715A1 |
Provided is a composition comprising Chlamydomonas reinhardtii or an extract of the Chlamydomonas reinhardtii, wherein the Chlamydomonas reinhardtii or the extract of the Chlamydomonas reinhardtii functions as an antagonist of an adrener...
|
|
WO/2023/054726A1 |
The present disclosure relates to: a pharmaceutical composition, a food composition, or a feed composition, containing monoclonal antibody that binds with enteric bacteria and being for the prevention or treatment of impairment or diseas...
|
|
WO/2023/051478A1 |
The present application discloses a dental gel having a remineralizing ability, a dental patch, and a method for preparing a dental gel. The dental gel comprises the raw material components of the following mass content: 1-35% of active ...
|
|
WO/2023/050716A1 |
Provided is weissella confusa WSG1 having the ability to assist digestion. The deposit number of the strain is CGMCC NO. 22697, and a nucleotide sequence of 16S rRNA is as shown in SEQ ID NO. 1. The strain can survive in the gastrointest...
|
|
WO/2023/055434A1 |
The present disclosure provides compositions of endolysin peptides used in combination with certain antibiotics, provides one or more of features and combinations thereof as described herein, and methods of use thereof.
|
|
WO/2023/053772A1 |
The present invention provides a proliferation promotor for a short-chain fatty acid-generating bacteria in the intestine, the proliferation promotor containing barley green leaves as an active ingredient. The present invention effective...
|
|
WO/2023/054666A1 |
The inventors found that a peptide derived from HMGB1 can be used as a drug for treating and/or preventing fatty liver, non-alcoholic steatohepatitis, and a variety of symptoms accompanying fatty liver. The present application provides, ...
|
|
WO/2023/055124A1 |
The present invention provides a bicyclic fused ring (for example, benzo[d]imidazole, benzo[d][1,2,3]triazole, or 8-oxo-8,9-dihydro-7H-purine) derivative or a pharmaceutically acceptable salt thereof, a method for preparing same, a pharm...
|
|
WO/2023/053123A1 |
A novel mRNA molecule encoding SIRT6, methods and uses thereof for treating diseases including fatty liver diseases, e.g., NASH.
|
|
WO/2023/056413A1 |
Generally, the present disclosure contemplates engineered vectors, organisms (e.g., bacteria or bacteriophage) containing the same, and methods for treating the gut of mammalian species by providing the organism containing the engineered...
|
|
WO/2023/055079A1 |
The present invention relates to a composition for preventing, alleviating, or treating metabolic syndromes such as obesity, diabetes, hyperlipidemia, and fatty liver, comprising, as an active ingredient, a carob extract, which is a natu...
|
|
WO/2023/051025A1 |
An application of Pulsatilla saponin B4 in the preparation of medicine for treating non-alcoholic fatty liver diseases. A medicine for treating non-alcoholic fatty liver diseases, which has an active ingredient of Pulsatilla saponin B4. ...
|
|
WO/2023/051805A1 |
A fluorinated phenylarsine oxide or a pharmaceutically acceptable salt thereof, relating to a pharmaceutical composition containing a pharmaceutically acceptable carrier and a fluorinated phenylarsine oxide. The fluorinated phenylarsine ...
|
|
WO/2023/047404A1 |
The present invention, in some embodiments, is directed to a method for producing a composition including a co-culture comprising a plurality of bacteria having a high similarity % to an origin sample and bacterial load.
|
|
WO/2023/046976A2 |
This invention relates to a composition useful in the treatment of liver disease, to methods for preparing the composition and its use in therapy. The composition comprises a combination of hepatocytes and mesenchymal stromal cells (MSCs...
|
|
WO/2023/049279A1 |
The disclosure relates to oral care compositions comprising guanidine in free or orally acceptable salt form and a stannous ion source (e.g., stannous fluoride) as well as to methods of using and of making these compositions.
|
|
WO/2023/045005A1 |
The present invention relates to a method for preparing total glucosides of Paeonia. The method comprises the following steps: 1) extraction: taking decoction pieces of radix paeoniae alba, extracting with ethanol, and filtering an extra...
|
|
WO/2023/049491A1 |
The present disclosure describes a method of reducing liver volume in a cirrhotic or non- cirrhotic subject, the method comprising administering resmetirom, a prodrug thereof, or a pharmaceutically acceptable salt of the resmetirom or th...
|
|
WO/2023/046885A1 |
There is provided herein compounds of formula I and pharmaceutically acceptable salts thereof, wherein R1, ring A and the ring containing Q1 to Q5 have meanings as provided in the description. There is also provided medical uses of such ...
|
|
WO/2023/048197A1 |
The present application provides an agent or composition for birds (for example, chickens), the agent or the composition containing, as an active ingredient, viable cells or dead cells of Lactobacillus plantarum (International Deposition...
|
|
WO/2023/049874A1 |
Glutaric aciduria type I (GA-1), is a rare neurometabolic organic aciduria caused by glutaryl-CoA dehydrogenase (GCDH) deficiency. It is an autosomal recessive inborn error of lysine and tryptophan catabolism. Disclosed herein are compos...
|
|
WO/2023/049268A1 |
Enterically-coated solid dosage forms containing a pharmaceutical agent which includes bacteria and/or microbial extracellular vesicles (mEVs) are provided. Methods of treatment using such solid dosage forms are also provided.
|
|
WO/2023/047317A1 |
A method of preventing or treating an inflammatory disease and/or conditions associated with inflammation and/or biomarkers associated with inflammation in a subject in need thereof is provided. Also provided are pharmaceutical compositi...
|
|
WO/2023/048277A1 |
Provided is a group 2 innate lymphoid cell growth inhibitor containing MAIT cells.
|
|
WO/2023/048526A1 |
The present invention relates to a pharmaceutical composition for preventing, alleviating or treating metabolic diseases, particularly, nonalcoholic steatohepatitis and liver fibrosis, the composition containing a novel inflammasome inhi...
|
|
WO/2023/045995A1 |
Multivalent ligand clusters, having a diamine scaffold, for targeted delivery of pharmaceutical agents conjugated thereto are described. A multivalent ligand cluster may comprise one or more N-acetylgalactosamine (GalNAc) targeting ligan...
|
|
WO/2023/049475A1 |
Among other things, the present disclosure provides designed oligonucleotides and compositions thereof. In some embodiments, oligonucleotides and compositions of the present disclosure can provide high levels of adenosine editing. In som...
|
|
WO/2023/044967A1 |
Provided is the use of a compound KYA1797K in the preparation of an anti-HBV viral drug. The anti-viral effect, particularly the anti-HBV effect, of the compound KYA1797K is found. Experiments show that the small molecule KYA1797K can in...
|
|
WO/2023/046055A1 |
Disclosed in the present invention are a substituted heterocyclic compound containing an α-ketone framework, and the use thereof, which relate to the field of medicinal chemistry. Specifically disclosed are a substituted heterocyclic co...
|
|
WO/2023/048125A1 |
A regenerative agent for bone tissue and lung tissue that contains a macrolide antimicrobial agent as an active ingredient. The macrolide antimicrobial agent may be one or more selected from the group consisting of erythromycin, azithrom...
|
|
WO/2023/048453A1 |
The present invention relates to nanoparticles comprising a drug dimer, and a use thereof. In addition, the nanoparticles may further comprise fucoidan. The nanoparticles comprising an obeticholic acid dimer compound can be used for trea...
|
|
WO/2023/049741A1 |
The present disclosure provides methods for identifying early-stage pancreatic cancer in a subject. The methods are based, in part, on the change of metabolic biomarker levels indicative of malignant or mucinous pancreatic cysts which ca...
|
|
WO/2023/048425A1 |
The present invention relates to a GFRAL-antagonistic antibody having improved affinity and a use thereof, and more particularly, the present invention relates to an anti-GFRAL antibody having improved affinity, comprising a heavy chain ...
|
|
WO/2023/048582A1 |
The present invention relates to a new class of methanogen inhibitors for ruminants, in particular new pyromellitic diimide derivatives for ruminants. The invention also extends to the use of such derivatives in ruminants to reduce metha...
|
|
WO/2023/044390A1 |
The present disclosure provides anti-Siglec-6 antibodies and their use in treating and preventing mast cell-mediated disorders, as well as compositions and kits comprising the anti-Siglec-6 antibodies.
|
|
WO/2023/040818A1 |
Disclosed are a RIPK1 inhibitor that inhibits programmed cell necrosis and a preparation method therefor. The disclosed RIK1 inhibitor is represented by general formula I, where X1, X2, X3, X4, X5, Z1, Z2, Z3, L1, L2, L3, R, R1, ring D a...
|
|
WO/2023/040422A1 |
The use of one or more strains of Lactobacillus reuteri PLBK®1, Lactobacillus reuteri PLBK®2, Lactobacillus gasseri PLBK®3, Lactobacillus acidophilus PLBK®4 and Bifidobacterium lactis PLBK®5 and fermentation cultures or metabolites ...
|
|
WO/2023/043836A1 |
Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, dis...
|
|
WO/2023/043272A1 |
The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, the pharmaceutical composition comprising an intestinal organoid and a TNFα inhibitor. The combined use of the ...
|
|
WO/2023/044290A1 |
Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2023/040077A1 |
Disclosed in the present invention are a fermented Ophiocordyceps sinensis powder with high adenosine and high ergosterol, and a production method therefor, which relate to the technical field of fermented Ophiocordyceps sinensis powders...
|
|
WO/2023/044135A1 |
Described herein are formulations for treating, preventing, or ameliorating one or more of irritable bowel syndrome (IBS), rheumatoid arthritis (RA), fibromyalgia, post-traumatic stress disorder, PTSD, neuropathic pain, or symptoms assoc...
|
|
WO/2023/040311A1 |
An application of a cationic polymer in the preparation of a drug for treating or preventing tumors. Oral administration of the cationic polymer can alleviate, treat and prevent various cancers, and alleviate complications thereof. Oral ...
|
|
WO/2023/044355A1 |
Specifically, the invention relates to compositions and methods for treating liver ailments, such as compositions and methods for attenuating or ameliorating the development of alcoholic liver disease (ALD), hepatic steatosis, liver oxid...
|
|
WO/2023/041357A1 |
The present invention relates to an extract of a plant of the species Rubus fruticosus or of any part of this plant. Furthermore, it relates to a composition comprising this extract and at least one orally acceptable carrier and optional...
|
